Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Agios Pharmaceuticals (AGIO) “announced that the U.S. Food and Drug Administration has approved AQVESME, or mitapivat, an oral pyruvate kinase ...

Pyruvate dictates redox balance and cell size, establishing metabolism as a dominant regulator of cellular fitness, unveiling new strategies to modulate cancer, regeneration, and diabetes.

Agios Pharma’s oral PK activator, Aqvesme receives US FDA approval to treat anaemia in adults with alpha- or beta-thalassemia: Cambridge, Massachusetts Friday, December 26, 2025 ...

US rare disease specialist Agios Pharmaceuticals (Nasdaq: AGIO) has won approval for Aqvesme (mitapivat) to treat anemia in adults with alpha- or beta-thalassaemia, covering both ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...

Pyruvate is produced by glycolysis, a process in which carbohydrates are broken down to create energy. Calcium pyruvate is a popular supplement that many people use primarily for its purported weight ...